Abstract Titles
Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Onsite Posters
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
| # | Type | Title | Authors | Category | Keywords | |
|---|---|---|---|---|---|---|
| 227 | Poster Presentation | A computational semi-mechanistic pharmacology model of ATG101, a PD-L1/4-1BB bispecific antibody for treatment of solid tumors and NHL | David C. Flowers, PhD; Marc Presler; Kas Subramanian; Theresa Yuraszeck; Hui Yuwen; Bing Hou, Ph.D; Dirk Hoenemann, MD | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Costimulation;Leukemia/Lymphoma;Solid tumors;Systems biology;Tumor infiltrating lymphocytes (TILs) | |
| 228 | Poster Presentation | Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity | Thomas Thisted, PhD; Arnab Mukherjee, PhD; Kanam Malhotra; Zuzana Biesova, PhD; Yuliya Kleschenko, PhD; Zhi-Gang Jiang, PhD; Anokhi Cifuentes; Nadthakarn Boland; Nels Nielson; Edward H. van der Horst, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;MDSC;Myeloid cells;T cell;Tumor microenvironment | |
| 229 | Poster Presentation | CX3CR1 in exhausted CD8 T cell states | Apoorvi Chaudhri, MS; Yunfei Wang; Shao-Hsi Hung; Gregory A. Lizee, PhD; Ulrich Von Andrian, MD, PhD; Patrick Hwu; Gordon J. Freeman, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Tumor infiltrating lymphocytes (TILs) | |
| 230 | Poster Presentation | Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology | Vanessa Gauttier, PhD; Marion Drouin; Sabrina Pengam; Javier Saenz; Bérangère Evrard; Stéphanie Neyton; caroline Mary; Géraldine Teppaz; Ariane Desselle; Virginie Thépénier; Emmanuelle Wilhelm; Nicolas Poirier; Elise Chiffoleau | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors | |
| 231 | Poster Presentation | Molecular Insights on safety and anti-tumor activity of a non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392 | Yang Liu, PhD; Yan Zhang; Xuexiang Du, PhD; Mingyue Liu, PhD; Xianfeng Fang, PhD; Libing Mu, PhD; Vadim Z. Tevetnitsky; Martin Devenport; Pan Zheng, MD, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Immune tolerance;Regulatory T cell (Treg cell);Tumor microenvironment | |
| 232 | Poster Presentation | INCB090244, a potent small molecule that inhibits the PD-L1/PD-1 axis and functions similarly to PD-L1 antibodies | Jonathan Rios-Doria, PhD; Alla Volgina; Prafulla C. Gokhale, PhD; Hao Liu; Christina N. Stevens; Nina Zolotarjova; Darlise DiMatteo; Kanishk Kapilashrami; Elham Behshad; Pramod Thekkat, MS; Gengjie Yang; Leslie Hall; Chrysi Kanellopoulou; Mark Rupar; Christopher Maddage; April Horsey; Krista Burke; Yan-ou Yang; Maryanne Covington; Steve Wang; Phillip Liu; Richard Wynn; David A. Reardon, MD; Holly K. Koblish, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;T cell;Targeted therapy | |
| 233 | Poster Presentation | Human PD-L2 triggers a unique T cell inhibitory program through PD-1 engagement distinct from that of PD-L1 | Anupallavi Srinivasamani, MS; Michael A. Curran, PhD; Qinying Liu; Shwetha M. Hegde; Chao-Hsien Chen, MD, PhD; Kimal Rajapakshe, PhD; Cristian Coarfa | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Coinhibition;Cytokine;Gene expression;T cell;Tumor microenvironment | |
| 234 | Oral Presentation | Distinct efficacy and immunological responses to αPD-1, ⍺PD-L1 and ⍺PD-L2 immunotherapy in aged versus young hosts | Yilun Deng, PhD; Harshita Gupta; Myrna G. Garcia, BS; Aravind Kancharla, MS; Ryan M. Reyes; Alvaro S. Padron; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Cytokine;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 235 | Poster Presentation | Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity | Yuji Mishima, PhD; Kanto Nakajima; Mamoru Shiraishi; Haruka Matsumura; Takahiko Aramaki; Noriko Matsumoto; Norihiro Nakamura | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Targeted therapy | |
| 236 | Poster Presentation | Predictors of ICI Renal Toxicity: A Pathological Approach | Ala Abudayyeh, MD; Liye Suo; Heather Lin, PhD; Omar Mamlouk; Cassian Yee, MD; Amanda Tchakarov; Jamie S. Lin, MD | Checkpoint Blockade Therapy | Autoimmunity;Immune toxicity;Inflammation | |
| 237 | Poster Presentation | Infectious complications in patients with non-small cell lung cancer treated with anti-PD(L)1 immune checkpoint inhibitors | Matthew Z. Guo, BA; Aanika Balaji, MD, MPH; Joseph C. Murray, MD, PhD; Joshua E. Reuss, MD; Seema A. Mehta Steinke, MD, MS; Jarushka Naidoo, MD, MHS | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Immune toxicity;Solid tumors | |
| 238 | Poster Presentation | Meta-analysis on the incidence of hyperprogressive disease during immune checkpoint inhibitor therapy | Seung Pyo D. Hong, MD; Min Jeong Kim, MD; Allison Belette, MD; Youjin Oh, MD; Sukjoo Cho, MD; Young Kwang Chae, MD, MPH, MBA | Checkpoint Blockade Therapy | Checkpoint blockade;Immune toxicity;Solid tumors | |
| 239 | Poster Presentation | Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged ≥80 years: a multicenter international cohort study | Caroline A. Nebhan, MD, PhD; Alessio AC. Cortellini, MD; Weijie Ma, MD; Teja Ganta, MD; Haocan Song, MS; Fei Ye, PhD; Rebecca Irlmeier, MS; Neha Debnath, MD; Anwaar Saeed, MD; Maluki Radford; Asrar Alahmadi, MBBS; Akiva Diamond, MD; Christopher J. Hoimes, MD; Nikhil Ramaiya, MD; Carolyn J. Presley; Dwight H. Owen; Sarah Abou Alaiwi, MD; Amin Nassar, MD; Biagio Ricciuti, MD; Giuseppe Lamberti, MD; Melissa Bersanelli, MD; Chiara Casartelli, MD; Sebastiano Buti, MD; Paolo Marchetti, MD; Raffaele Giusti; Marco Filetti; Vito Vanella; Domenico Mallardo, MD; Shravanti Macherla, MD; Tamara A. Sussman, MD; Andrea Botticelli, MD, PhD; Domenico Galetta, MD; Annamaria Catino, MD; Pamela Pizzutilo, MD; Carlo Genova, MD, MD; Maria Giovanna Dal Bello, MD; Foteini Kalofonou, MD, PhD; Ella Daniels; Paolo A. Ascierto, MD; David J. Pinato, MD, MRes, PhD; Toni K. Choueiri, MD; Douglas B. Johnson, M.D.; Thomas U. Marron, MD, PhD; Yinghong Wang, MD, PhD; Abdul Rafeh Naqash, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune toxicity;Solid tumors | |
| 240 | Poster Presentation | Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling. | Myrto Moutafi, MD; Sandra Martinez-Morilla, PhD; Prajan Divakar; Ioannis A. Vathiotis, MD; Niki Gavrielatou, MD; Thazin N. Aung, PhD; Vesal Yaghoobi, MD; Aileen I. Fernandez, PhD; Jon Zugazagoitia Fraile, MD; Kurt A. Schalper, MD, PhD; David L. Rimm, MD, PhD | Checkpoint Blockade Therapy | Antibody;Biomarkers;Checkpoint blockade;Solid tumors;Tumor microenvironment;Tumor stroma | |
| 241 | Poster Presentation | Immune Checkpoint Blockade (ICB) in Brain Metastases (BM) from Advanced Small Cell Urothelial Cancer (aSCUC) | Nathaniel R. Wilson, MD; Omar Alhalabi, MD; Elshad Hasanov; Lianchun Xiao; John Papadopoulos, MD; Matthew T. Campbell, MD; Amishi Shah; Jianjun Gao, MD PhD; Paul G. Corn, MD, PhD; Ana Aparicio; Jennifer Wang, MD; Bogdan A. Czerniak; Charles C. Guo; Christopher J. Logothetis, MD; Jing Li; Seungtaek Choi; Chad Tang, MD, MS; Nizar M. Tannir, MD, FACP; Arlene O. Siefker-Radtke, MD | Checkpoint Blockade Therapy | Chemotherapy;Clinical study;Radiotherapy;Solid tumors | |
| 242 | Poster Presentation | Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive | Haiyan HB. Bai, PhD; Álvaro Padrón; Yilun Deng, PhD; Anand Kornepati; Srikanth R. Polusani; Suresh C. Kari, PhD; Clare E. Murray; Myrna Garcia; Ryan M. Reyes; Niannian Ji; Harshita Gupta; Matthew J. Hart; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;NK/NKT cell;Post-translational modifications;T cell | |
| 243 | Poster Presentation | Understanding and overcoming the mechanism of resistance to anti-PD-1 monotherapy in brain metastasis | Laura Falceto Font, BS; Catherine Flores; Jack Figg; Bayli DiVita Dean; Connor Francis; Carmelle Kuizon; Ginger Moore | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;Tumor evasion | |
| 244 | Poster Presentation | Genomic determinants of response to chemoradiation and durvalumab consolidation for stage III non-small cell lung cancer | Matthew Z. Guo, BA; Joseph C. Murray, MD, PhD; Paola Ghanem, MD; Khinh Ranh Voong, MD, MPH; Russell K. Hales, MD; Josephine L. Feliciano, MD; Kristen A. Marrone, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;Radiotherapy;Solid tumors | |
| 245 | Poster Presentation | Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1 | Ann Hanna, PhD; Xiaopeng Sun, BS; Paula I. Gonzalez-Ericsson, MD; Violeta I. Sanchez, BS; Melinda I. Sanders, MD; Justin M. Balko, PharmD, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Chemotherapy;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 246 | Poster Presentation | Effectiveness and utilization of first-line immune checkpoint inhibitors for patients with extracranial & intracranial metastatic melanoma | Nayan Lamba, MD; Bryan Iorgulescu, MD | Checkpoint Blockade Therapy | Checkpoint blockade | |
| 247 | Poster Presentation | The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo | Stephan J. Matissek, PhD; Marisella Panduro Sicheva; Secil Koseoglu, PhD; Ricard Masia, MD PhD; Michael C. Warren; Matthew P. Rausch, PhD; Benjamin H. Lee, MD PhD; Sandra Pommey; Isabelle Cousineau, PhD; John Stagg; Vito J. Palombella, PhD; Andrew C. Lake, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Tumor microenvironment | |
| 248 | Poster Presentation | Empiric profiling of peripheral T cell recall responses to tumor mutanomes versus in silico predictions in NSCLC patients undergoing pembrolizumab treatment ± chemotherapy | Madison Milaszewski, BS; James Loizeaux; Emily Tjon, M.S.; Crystal Cabral, BS, MSc; Tulin Dadali, PhD; Justin Strickland; Jamie Foti, PhD; Kevin J. Mancini, MS; Kesi Michael; Louisa Dowal, PhD; Vijetha Vemulapalli; Alberto Visintin, PhD; Thomas A. Davis, MD; Jessica B. Flechtner, PhD; Mark Awad, MD, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Neoantigens;T cell | |
| 249 | Poster Presentation | Characterization of unresectable and/or metastatic solid tumors patients treated with systemic anticancer therapy in first-line settings: A Pan-tumor community-oncology based study | Elise Wu, PhD; Sneha Sura, MS, PhD; Alexander I. Spira, MD, PhD, FACP | Checkpoint Blockade Therapy | Checkpoint blockade;Chemotherapy;Epidemiology;Solid tumors | |
| 250 | Poster Presentation | Spatial-transcriptomic analysis of tumor-immune microenvironment in AML patients receiving pembrolizumab and decitabine | Chen Zhao, MD; Abigail Wong-Rolle, BSc; Prajan Divakar; Katherine R. Calvo, MD, PhD; Christopher S. Hourigan, MD, PhD | Checkpoint Blockade Therapy | Chemotherapy;Immune monitoring;Leukemia/Lymphoma;RNA;T cell;Tumor microenvironment | |
| 251 | Poster Presentation | The Use of Small Molecule Inhibitors to Target Novel Pathways in Exhausted T Cells for Immuno-Oncology Therapeutic Intervention | Francis Acklam; Joanne Hay; Darryl Turner; Mark Barbour; Preeti Singh; Courtney Grant; Hayley Gooding; Justyna Rzepecka; Rhoanne McPherson | Checkpoint Blockade Therapy | Bispecifics;Checkpoint blockade;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 252 | Poster Presentation | Novel DNAM-1 axis member, PVRIG, is potentially a dominant checkpoint involved in stem-like memory T cells – dendritic cell interaction | Zoya Alteber, PhD; Gady Cojocaru; Masha Frenkel; Emmanuel Weyl; Niv Sabath; Assaf Wool; Amit Novik; Yossef Kliger; Zurit Levine; Eran Ophir, PhD | Checkpoint Blockade Therapy | Antibody;Antigen presenting cells;Checkpoint blockade;Dendritic cell;Gene expression;Immune monitoring;Immune suppression;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 253 | Poster Presentation | PD1 and LAG3 converge to limit polyfunctionality and systemic immunity | Lawrence P. Andrews, PhD; Sasikanth Manne, PhD; E. John Wherry, PhD; Creg Workman, PhD; Dario A. Vignali, PhD | Checkpoint Blockade Therapy | Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 254 | Poster Presentation | NTX-1088, A POTENT ANTI-PVR MAB INDUCES DNAM1-MEDIATED ANTITUMOR IMMUNITY | Anas Atieh; Akram Obiedat, PhD; Guy Cinamon, PhD; Tihana Lenac Rovis; Paola Kucan Brlic; Lea Hirsl; Ofer Mandelboim, PhD; Stipan Jonjic, MD; Keren Paz, PhD; Pini Tsukerman, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Clinical trial;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 255 | Poster Presentation | Investigating VISTA's role intrinsic to T cells in the tumor microenvironment | Cassandra K. Gilmour, BS; Li Wang, PhD; Juan Dong, MD; Sarah Stone; Keman Zhang; Hieu M. Ta, Ph D | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 256 | Poster Presentation | The TIGIT/CD226/CD155 axis and the effects of combining PD-1/PD-L1 blockade with TIGIT-targeting antibody therapy in syngeneic murine glioblastoma models | Prafulla C. Gokhale, PhD; Bryan Iorgulescu, MD; Max Klapholz; Michael Poitras; Benjamin Eschle; Gordon J. Freeman, PhD; Ana C. Anderson, PhD; David A. Reardon, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs) | |
| 257 | Poster Presentation | Combination of Adenosine antagonists A2AR (TT-10) and A2BR (TT-4) with checkpoint inhibitors demonstrate anti-tumor activity in CT-26 Murine Colon Tumor Allograft Model | Desa Rae E. Pastore, MS, BS; Sushant Kumar, PhD; Brian Schwartz; Kasim Mookhtiar; Vijay Reddy | Checkpoint Blockade Therapy | Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs) | |
| 258 | Poster Presentation | AB308 is an Anti-TIGIT Antibody That Enhances Immune Activation and Anti-tumor Immunity Alone and in Combination with Other I-O Therapeutic Agents | Dana Piovesan, MSc; Alejandra Lopez, BSc; Patrick G. Schweickert, PhD; Ferdie Soriano, BS; Soonweng Cho, PhD; Ada Chen, BS; Hema Singh; Xiaoning Zhao; Stephen W. Young; Nigel P. Walker, PhD; Matthew J. Walters, PhD; Kelsey E. Sivick Gauthier, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;T cell;Tumor microenvironment | |
| 259 | Poster Presentation | Injectable chitosan hydrogel for localized delivery of immune checkpoint inhibitors | Siena M. Mantooth, BS; David A. Zaharoff, PhD | Checkpoint Blockade Therapy | Solid tumors;Targeted therapy;Tumor microenvironment | |
| 260 | Poster Presentation | CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics | Gabriela Andrejeva, PhD; Benjamin J. Capoccia, Ph.D; Rachel B. Delston, PhD; Michael J. Donio, MS; Ronald R. Hiebsch, BS; Robyn J. Puro, PhD; Casey Wilson, PhD; Arun K. Kashyap, PhD; Daniel S. Pereira, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Targeted therapy | |
| 261 | Oral Presentation | A functional genetic screen uncovers regulators of intratumoral macrophage function and reveals CD24 as a novel target for cancer immunotherapy by macrophages | Amira Barkal, MD, PhD; Rachel Brewer, MS; Irving L. Weissman, MD | Checkpoint Blockade Therapy | Monocyte/Macrophage;Myeloid cells | |
| 262 | Poster Presentation | Preclinical characterization of humanized anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression | Huyen Dinh; Sam Lam; Valerie Wall, PhD; Francisco Zapata; Darbie Whitman; Ramya Chandrasekaran; Lauren Loh; Texia Loh; Tom Graddis, PhD; Peter Probst; Myriam N. Bouchlaka, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 263 | Poster Presentation | ASD141, an innate checkpoint inhibitor, modulates tumor associated myeloid cells through CD11b and enhances current immune checkpoint blockade in preclinical model | Chia-Ming Chang, PHD; ??? Mr. Jason, MD; I-Fang Tsai, MS; Yen-Ta Lu, MD, PHD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Immune suppression;Myeloid cells;Solid tumors;Tumor microenvironment | |
| 264 | Poster Presentation | SIRPa blockade synergizes with radiation therapy in murine breast cancer models | Maud Charpentier, PhD; Claire Lhuillier; Ines Mota; Sergio Trombetta; Sandra Demaria, MD | Checkpoint Blockade Therapy | Antigen presenting cells;Dendritic cell;Tumor evasion;Tumor microenvironment | |
| 265 | Poster Presentation | CD47xPD-L1 bispecific antibodies for cancer therapy | Xavier CHAUCHET, PhD; Elise PENARRIETA; Nicolas BOSSON; Sébastien CALLOUD; Louis HELLEQUIN; Margaux LEGRAND; Alizée VIANDIER; Françoise RICHARD; Laura CONS; Pauline MALINGE; Tereza BAUTZOVA; Jérémie BOURGUIGNON; Guillemette PONTINI; Mengzhu SUN; Ulla RAVN; Valéry MOINE; Yves POITEVIN; Stéphanie HUGUES; Nicolas FISCHER; Limin SHANG; Walter G. FERLIN; Krzysztof MASTERNAK | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Monocyte/Macrophage;Solid tumors;T cell | |
| 266 | Poster Presentation | AK117, A CD47 Blocking Antibody with Robust Macrophage Activation without Red Blood Cell Hemagglutination | Zhaoliang Huang, BSc; Xinghua Pang, BSc; Tingting Zhong, MS; Tailong Qu; Chunshan Jin; na chen, MD; Xinrong He; Dennis Xia, Ph.D; Xiaoping Jin, PhD; Zhongmin Wang; Xu Xia; Baiyong Li, Ph.D | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Monocyte/Macrophage;T cell | |
| 267 | Poster Presentation | Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes anti-tumor immunity and improves therapeutic window | Shih-Hsun Chen, PhD; Pawel Dominik; Jessica Stanfield; Sheng Ding; Wenjing Yang; Ryan Llewellyn; Jonathan Heyen; Carole Wang; Zea Melton; Kevin Lindquist; Thomas Van Blarcom; Javier Chaparro-riggers; Shahram Salek-Ardakani | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antibody;Bispecifics;Checkpoint blockade;Dendritic cell;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment | |
| 268 | Poster Presentation | KVA 12.1 a novel fully human anti-VISTA antibody: Clinical trial design in monotherapy and in combination with an anti-PD1 antibody | Thierry Guillaudeux, PhD; Shawn Iadonato, PhD; Eric Tarcha, PhD; Craig Philips | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Clinical trial;Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment | |
| 269 | Poster Presentation | Utilizing serum proteome to understand response and resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer | Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA; Dong-Uk Lee | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Clinical study | |
| 270 | Oral Presentation | Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis | Jessica D. Mackert, PhD; Elizabeth R. Stirling, MS; Mitra Kooshki, MS; Dawen Zhao, MD; PhD; Alexandra Thomas, MD; Glenn Lesser, MD; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Gene expression;Monocyte/Macrophage;Solid tumors | |
| 271 | Poster Presentation | Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages | Peter Probst; Randi Simmons; Huyen Dinh; Meghan E. Zuck, PhD; Valerie Wall, PhD; Myriam N. Bouchlaka, PhD; Sam Lam; Ray Fox; Darbie Whitman; Tom Graddis, PhD; Kamal D. Puri, PhD | Checkpoint Blockade Therapy | Antibody;B cell;Checkpoint blockade;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor evasion;Tumor microenvironment | |
| 272 | Poster Presentation | A Novel Bispecific Macrophage Engager Antibody (BiME) Designed for Cancer Immunotherapy | Hongtao Lu, PhD; Dawei Sun, Ph.D.; Xiaofeng Niu, Ph.D.; Yanan Geng; Jing Wang; Haixia Jiang; Rui Gao, Ph.D.; Zhihao Wu, Ph.D; Yangsheng Qiu, PhD | Checkpoint Blockade Therapy | Antibody;Antigen presenting cells;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy | |
| 273 | Poster Presentation | Application of pharmacokinetic-pharmacodynamic modeling to select the optimal dose of ALX148, a CD47 blocker. | Oleg Demin Jr, MSc; Elena Vasileva | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Leukemia/Lymphoma;Monocyte/Macrophage | |
| 274 | Poster Presentation | CD47 x EpCAM Bispecific Antibody Represents a Novel Approach for Treating EpCAM Overexpressing Solid Tumors | Xinhua Wang, Ph.D; Oi Kwan Wong, Ph.D; Lei Shi; Qi Fei; Leonard Post; Xiaocheng Chen, PhD | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Solid tumors | |
| 275 | Poster Presentation | Flow cytometry and NanoString provide a comprehensive cell- and gene-based tumor profile following checkpoint inhibition in a murine bladder cancer model | David W. Draper, PhD; Philip E. Lapinski, PhD; Scott Wise, BS | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Chemokine;Cytokine;Immune monitoring;Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 276 | Poster Presentation | Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression | Meghan E. Zuck, PhD; Huyen Dinh; Valerie Wall, PhD; Sam Lam; Ramya Chandrasekaran; Francisco Zapata; Texia Loh; Lauren Loh; Myriam N. Bouchlaka, PhD; Tom Graddis, PhD; Kamal D. Puri, PhD; Peter Probst | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Myeloid cells;T cell;Tumor microenvironment | |
| 277 | Poster Presentation | Safety and Efficacy of Intratumoral Ipilimumab with IV Nivolumab in Metastatic Melanoma. The NIVIPIT Trial. | Lambros Tselikas, MD; Caroline Robert, MD, PhD; Stephane Dalle; Nicolas Meyer; Celeste Lebbe, MD, PhD; Samy Ammari; François-Xavier Danlos; Severine Roy; Camille Jannin; Siham Farhane; Severine Mourad; Guillaume Escriou; Thibault Raoult; Jean-Yves Scoazec, MD; Matthieuu Texier; Nathalie Chaput-Gras; Laurence Zitvogel, MD, PhD; Thierry De Baere, MD, PhD; Aurélien Marabelle | Checkpoint Blockade Therapy | Antibody;Biomarkers;Checkpoint blockade;Chemokine;Immune monitoring;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment | |
| 278 | Poster Presentation | Systematic review and meta-analysis evaluating the impact of antibiotic use on clinical outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors | Athéna Crespin; Athéna Crespin, Engineer; Pierre-Alain Bandinelli; Clément Le Bescop; Renaud Buffet; Jean De Gunzburg; Fabien Vitry; Gérard Zalcman; Julie Cervesi, PharmD | Checkpoint Blockade Therapy | Checkpoint blockade;Microbiome;Solid tumors | |
| 279 | Poster Presentation | ILT3 blockade reduces tumor blast cells in Acute Myeloid Leukemia PBMC and inhibits tumor cell growth in a humanized AML tumor model | Alan J. Byford, MS; Yujie Qu; Haiyan Xu, MD PhD; Gain Robinson; Latika Singh; Eric Muise, MS; Elaine Pinheiro, PhD; Mei Chen, MD; Lily Moy; Stephen Alves, PhD; Jie Zhang-Hoover, PhD | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells | |
| 280 | Poster Presentation | Clinical Outcomes of Immunotherapy Continued Beyond Radiographic Progression In Older Adults with Advanced Non-Small Cell Lung Cancer | Eric K. Singhi, MD; Frank Mott; Michelle A. Worst, PharmD, BCOP, MBA; Cheuk Hong Leung; Jack J. Lee, PhD/DDS; Brett Carter; Carolyn J. Presley; Jeff Lewis; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; Jianjun Zhang, MD, PhD; Don L. Gibbons, MD, PhD; Ara A. Vaporciyan, MD; John V. Heymach, MD, PhD; Mehmet Altan | Checkpoint Blockade Therapy | Checkpoint blockade | |
| 281 | Poster Presentation | Measuring immune checkpoint inhibitor efficacy using primary patient-derived 3D spheroids | Kathryn M. Appleton, PhD; Katy A. Lassahn, MS; Ashley K. Elrod; Tessa M. DesRochers, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 282 | Poster Presentation | Bispecific antibodies (BsAbs) targeting ABCB1/PgP and CD47 provide a multi-modal, tumor specific approach to combat drug resistant cancers. | Robert Arathoon, PhD; Raffaella Briante, PhD; Alissa O'Connor; Cindy Tan; Pamela Klein, MD; Jessica Morgan, PhD; Paul Ponath, PhD; Leonard Presta; Qianting Zhai; Suchismita Mohanty; Pinping Zhang | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Chemotherapy;Solid tumors;Targeted therapy;Tumor antigens | |
| 283 | Poster Presentation | TIM-3 blockade modulates the tumor microenvironment improving the outcome of preclinical pediatric Diffuse Midline Glioma models | Iker Ausejo-Mauleon, MSc; Sara Labiano, MSc; Virginia Laspidea; Marc Garcia-Moure; Daniel de la Nava; Oren J. Becher; Mariella G. Filbin; Fernando Pastor; Marta M. Alonso | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Immune suppression;NK/NKT cell;Pediatric tumors;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 284 | Poster Presentation | Integrated Molecular Characterization of primary resistance mechanisms to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Carcinoma (a-NSCLC) | Benjamin Besse, MD, PhD; Colette DIB, PhD; Eladio J. Marquez, Ph.D.; Joon Sang Lee, PhD; Shu Yan; Marielle Chiron, PhD; Cecile N. Combeau, Ph D; Angelique Biancotto; Félix Blanc-Durand; Mihaela Aldea; David Planchard, MD, PhD; Jean-Yves Scoazec, MD; Ludovic Lacroix, PharmD; Etienne Rouleau, MD; Nathalie Chaput-Gras; Saloomeh Rafie; Aurélien Marabelle; Eric Angevin, MD, PhD; Jack Pollard, PhD | Checkpoint Blockade Therapy | Bioinformatics;Checkpoint blockade;Gene expression;Immune contexture;RNA;Tumor microenvironment | |
| 285 | Poster Presentation | Breaking through the resistance of breast cancer to immune checkpoint blockers in a unique mouse model of HR+ disease | Norma Bloy, PhD; Aitziber Buqué Martinez, PhD; Bhavneet Binder; Giulia Petroni; Takahiro Yamazaki, PhD; Ai Sato; Olivier Elemento, PhD; Silvia C. Formenti, MD; Lorenzo Galluzzi, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune contexture;Immune monitoring;Solid tumors | |
| 286 | Poster Presentation | Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC). | Poromendro Burman, MS; Boyang Zhang; Zhicheng Ji; Justina Caushi; Frank Housseau; Andrew M. Pardoll, MD, PhD; Zhang Jiajia; Hongkai Ji; Kellie Smith | Checkpoint Blockade Therapy | Bioinformatics;Checkpoint blockade;Clinical study;Gene expression;RNA;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 287 | Poster Presentation | Combined COX-2 inhibition with fish oil and aspirin as adjuncts to anti-PD-1 immunotherapy in metastatic melanoma | Alexander C. Chacon, MD; Alexa D. Melucci, MD; Shuyang S. Qin, M.S; Paul R. Burchard, MD; Katherine M. Jackson, M.D.; Rachel Jewell; Peter A. Prieto, MD, MPH | Checkpoint Blockade Therapy | Checkpoint blockade;Inflammation;Metabolism;Monocyte/Macrophage;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 288 | Poster Presentation | The COX-2 pathway as a mediator of resistance to anti-PD-1 therapy | Shuming Chen, PhD, MB; Tracee L. McMiller, MS; Preethi Sankaran; Kyle Kampta; Suzanne L. Topalian, MD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR;Tumor evasion;Tumor microenvironment | |
| 289 | Poster Presentation | Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone | Zhaoliang Huang, BSc; Xinghua Pang, BSc; Tingting Zhong, MS; na chen, MD; Xinrong He; Dennis Xia, Ph.D; Xiaoping Jin, PhD; Zhongmin Wang; Xu Xia; Baiyong Li, Ph.D | Checkpoint Blockade Therapy | Antibody;Bispecifics;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;T cell | |
| 291 | Poster Presentation | Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity | Coline A. Couillault, PhD; Anupallavi Srinivasamani, MS; Shweta M. Hedge; Qinying Liu; Ashwin Jaiswal; Dongxing Zha; Michael A. Curran, PhD | Checkpoint Blockade Therapy | Bispecifics;Checkpoint blockade;Coinhibition;Immune suppression;MDSC;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 292 | Poster Presentation | Ex vivo profiling of PD-1 blockade using an organotypic tissue slice model in Solid Tumors | Lina Ding, PHD; Kristin Sullivan; Chensheng Zhou; Jimena Trillo-Tinoco; anne lewin; Catherine King; David Nelson; Benjamin J. Chen, MD, PhD; Michaela Bowden | Checkpoint Blockade Therapy | Biomarkers;Cytokine;Solid tumors;T cell;Tumor microenvironment | |
| 293 | Poster Presentation | Distinct tumor infiltrating Treg lineages are associated with response to anti-PD1 checkpoint blockade in non-small cell lung cancer. | Arbor G. Dykema, BS; Boyang Zhang, BS; Jiajia Zhang, MD, MPH; Zhicheng Ji; Taibo Li, MS; BS; Poromendro Burman, MS; Justina Caushi; Hongkai Ji; Andrew M. Pardoll, MD, PhD; Kellie N. Smith, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Immune toxicity;Regulatory T cell (Treg cell);T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 294 | Poster Presentation | Evaluation of radiographic response in the intact renal mass (intact-Rmass) to immune checkpoint inhibitor (ICI) combination regimens in patients with metastatic renal cell carcinoma (mRCC) | Hamid Emamekhoo, MD; Danubia Hester; Saqib Abbasi; Jens Eickhoff, PhD; Tristan Bice; Luna Archaya; Ellen B. Jeager; Moshe C. Ornstein; Ali Pirasteh; Pedro Barata, MD, MSc; Yousef Zakharia; Deepak Kilari; Elizabeth Wulff-Burchfield; Christos E. Kyriakopoulos, MD | Checkpoint Blockade Therapy | Angiogenesis;Checkpoint blockade;Clinical study;Targeted therapy | |
| 295 | Poster Presentation | Tumor cell- intrinsic expression of FGFR3 drives anti-PDL-1 immunotherapy resistance in a murine bladder cancer model | Erica Fleming-Trujillo, PhD; Jeffrey C. Bloodworth; Anthony Fernald; Aubrianna Ramsland; Thomas F. Gajewski, MD, PhD; Randy F. Sweis, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Solid tumors;Tumor evasion;Tumor microenvironment | |
| 296 | Poster Presentation | A comprehensive clinical and genomic characterization of long-term responders receiving immune checkpoint blockade for metastatic non-small cell lung cancer | Paola Ghanem, MD; Joseph C. Murray, MD, PhD; Melinda Hsu; David S. Ettinger, MD; Josephine L. Feliciano, MD; Patrick Forde; Christine L. Hann, MD, PhD; Vincent K. Lam, MD; Benjamin P. Levy; Julie R. Brahmer, MD, MS; Kristen A. Marrone, MD | Checkpoint Blockade Therapy | Checkpoint blockade;Clinical study;Solid tumors | |
| 298 | Poster Presentation | Tumor cell-intrinsic mTORC1 signaling through Raptor makes melanoma and ovarian cancer immunotherapy resistant by regulating interferon-gamma responsiveness and promoting tumor-initiating cells | Harshita Gupta; Suresh C. Kari, PhD; Emily L. Salinas, BS; Haiyan HB. Bai, PhD; Erica Osta, BS; Anand Kornepati; Juan Wang; Xinyue Zhang; Yidong Chen; Ratna Vadlamudi; Tyler J. Curiel, MD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Cytokine;Solid tumors;Stem cell/cancer-initiating cell;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 299 | Poster Presentation | Broad T antigen-specific CD8+ T cell repertoire is associated with response to PD-1 blockade in virus positive Merkel Cell Carcinoma | Ulla K. Hansen, PhD; Candice D. Church, PhD; Amalie K. Bentzen; Steven P. Fling, PhD; Nirasha Ramchurren, PhD; Suzanne L. Topalian, MD; Paul T. Nghiem, MD, PhD; Sine R. Hadrup, Prof | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Immune monitoring;T cell;Targeted therapy;Tumor antigens | |
| 300 | Oral Presentation | Longitudinal plasma proteomic profiling of non-small cell lung cancer patients undergoing immune checkpoint blockade-based therapy | Michal Harel, PhD; Coren Lahav; Eyal Jacob, PhD; Itamar Sela, PhD; Yehonatan Elon, PhD; Galit Yahalom, PhD; Iris Kamer, PhD; Ofer Sharon, MD; Yuval Shaked, PhD; Adam P. Dicker, MD, PhD; David P. Carbone, MD, PhD; Jair Bar, MD, PhD | Checkpoint Blockade Therapy | Bioinformatics;Biomarkers;Checkpoint blockade;Proteomics;Systems biology | |
| 301 | Poster Presentation | OMX-0407, a highly potent SIK3 inhibitor, sensitizes tumor cells to apoptosis and eradicates tumors in combination with PD-1 inhibition | Christina Hartl; Tillmann Michels; Ronny Milde; Vanessa Klein; Philipp Beckhove; Hannes Loferer; Stefan Bissinger, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 302 | Poster Presentation | Characterization of TIGIT and PVR expression in colorectal liver metastases | Antoine BERNARD, PhD; David Henault; Sandy Pelletier; Pamela Thebault; Benoit Barrette; Simon Turcotte, MD, MSc | Checkpoint Blockade Therapy | Checkpoint blockade;Gene expression;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 303 | Poster Presentation | Non-functional T cell responses in non-small cell lung cancer are induced during tumor antigen-specific T cell priming in the mediastinal lymph node | Brendan L. Horton, PhD; Duncan Morgan; Elen Torres-Mejia, PhD; Maria Zagorulya, B.S.; Vidit Bhandarkar; Noor Momin; K. D. Wittrup; J C. Love; Stefani Spranger, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Cytokine;Gene expression;Immune contexture;Solid tumors;T cell;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 304 | Poster Presentation | Antagonistic antibodies targeting LAIR1 enhance T lymphocyte activation and promote inflammatory phenotypes in myeloid cells | Tao Huang, PhD; Caroline Bonnans, PhD; Maria Jose Costa, PhD; Azita Tabrizi; Jing-Tyan Ma; Jingjing Xie; Heyu Chen, PhD; Kyu Hong; Krista McCutcheon; Ryan Stafford; Hongyu Tian; Cheng Cheng Zhang, PhD; Xun Gui; Ningyan Zhang; Zhiqiang An, PhD; X. Charlene Liao; An Song, PhD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment | |
| 305 | Poster Presentation | Unravelling the role of CD4+ and CD8+ T cells in Pembrolizumab Induced Mycobacterium Tuberculosis Granuloma Formation in Nasopharyngeal Carcinoma | Tae Yang Desmond Hung, Mphil; Ngar Woon Kam; Victor Ho Fun Lee | Checkpoint Blockade Therapy | Checkpoint blockade;NK/NKT cell;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 306 | Poster Presentation | Decr2 regulates tumor cell ferroptosis and is required for immunotherapy efficacy | Shuyin Li, PhD; Thomas F. Gajewski, MD, PhD; Emily Higgs | Checkpoint Blockade Therapy | Checkpoint blockade | |
| 307 | Poster Presentation | Interaction of anti-PD-1/PD-1 immunocomplexes with human FcRs: binding properties and functional implication | Elena Daveri, PhD; Elena Luison; Viviana Vallacchi; Barbara Vergani; Veronica Huber; Agata Cova; Biagio Eugenio Leone; Marina Garassino; Mariangela Figini; Licia Rivoltini | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Myeloid cells;Tumor evasion | |
| 308 | Poster Presentation | Transcriptomic analysis of melanoma patients in adjuvant setting treated with Anti PD1 therapy: real life study | Domenico Mallardo, MD; Claudia Trojaniello; Maria Grazia Vitale, MD; grazia d'angelo; Andrew M. White, BSc; Mariaelena Capone, MD; Antonio Sorrentino, MD; Gabriele Madonna, MS; Marilena Tuffanelli; Vito Vanella; Lucia Festino; Ester Simeone, MD; Corrado Caracò; Nicola Normanno; Sarah E. Warren, PhD; Paolo A. Ascierto, MD | Checkpoint Blockade Therapy | Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Carcinogenesis;Gene expression;Immune adjuvant;Immune suppression;T cell lineages | |
| 309 | Poster Presentation | Visualizing the immunotherapy-induced spatial reorganization of the tumor-immune microenvironment by CODEX multiplex imaging | Ruan FV. MEDRANO, PhD; Fei Han; Bassem Ben Cheikh; Patrick Leinert Jr; Wm. Pat Leinert Sr; Oliver Braubach; Robert D. Schreiber, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 310 | Oral Presentation | T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade. | Yuki Muroyama, MD, PhD; Sasikanth Manne, PhD; Allison R. Greenplate, PhD; Divij Mathew, PhD; Derek A. Oldridge, MD, PhD; Lakshmi Chilukuri; Caiyue Xu; Ramin S. Herati, MD; Alexander C. Huang, MD; Dimitriy Zamarin, MD, PhD; Claire F. Friedman, MD; E. John Wherry, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Immune monitoring;T cell | |
| 312 | Poster Presentation | Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90% | Biagio Ricciuti, MD; Joao Victor M. Alessi, MD; Stephanie L. Alden; Giuseppe Lamberti, MD; Victor R. Vaz; Adriana Barrichello; Lynette M. Sholl, MD; Mark Awad, MD, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade | |
| 313 | Poster Presentation | Stealthier mutanomes are induced after nivolumab immunotherapy | Guilhem Richard, PhD; Michael F. Princiotta, PhD; Gary D. Steinberg, MD; William Martin, BA MD; Anne S. de Groot, MD | Checkpoint Blockade Therapy | Bioinformatics;Checkpoint blockade;Immune tolerance;Neoantigens;Regulatory T cell (Treg cell);T cell;Tumor antigens;Tumor evasion | |
| 314 | Poster Presentation | NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer | Berengere Salome, PharmD, PhD; John P. Sfakianos, MD; Andrew Charap; Adam M. Farkas, PhD; Daniel Geanon; Geoffrey Kelly; Ronaldo de Real; Brian Lee; Kristin G. Beaumont; Sanjana Shroff, PhD; Ying-Chih Wang; Yuan-Shuo A. Wang; Robert Sebra; Li Wang, PhD; Alice O. Kamphorst, PhD; Karl-Johan Malmberg, MD, PhD; Emanuela Marcenaro, PhD; Pedro J. Romero, MD; Rachel Brody, MD, PhD; Yuko Yuki; Maureen Martin, MD; Mary Carrington, PhD; Reza Mehrazin, MD; Peter Wiklund, MD; Jun Zhu, PhD; Matthew D. Galsky, MD; Nina Bhardwaj, MD, PhD; Amir Horowitz, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 315 | Poster Presentation | Application of the SITC Immunotherapy Resistance Taskforce definitions of anti-PD-1 resistance to studies evaluating patients with advanced melanoma | Irene Shui, ScD; Emilie Scherrer, MSc; Andrew M. Frederickson, MS; Eric Druyts, MSc; Hussein A. Tawbi, MD, PhD | Checkpoint Blockade Therapy | Biomarkers;Checkpoint blockade;Epidemiology;Solid tumors;Targeted therapy | |
| 316 | Poster Presentation | Leucine-rich repeats and immunoglobulin-like domains protein 1 is highly expressed on tumor-infiltrating T cells and may play a role in modulating T cell activation | Li Wang, PhD; Timothy A. Chan, MD, PhD; Cassandra K. Gilmour, BS; Keman Zhang; Tyler J. Alban; Hieu M. Ta, Ph D | Checkpoint Blockade Therapy | Checkpoint blockade;T cell | |
| 317 | Poster Presentation | An immunosuppressive tumor population drives global and regional patterns of immune infiltration in heterogeneous tumors | Miho Tanaka, Ph.D.; Lotus Lum, B.Sc.; Zoe Adams, B.Sc.; Kenneth Ng, B.Sc.; Daphne Superville, B.Sc.; Melissa Reeves, Ph.D. | Checkpoint Blockade Therapy | Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment | |
| 318 | Poster Presentation | Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance | Brandie C. Taylor, MS; Justin M. Balko, PharmD, PhD; Melinda Sanders, MD; Paula I. Gonzalez-Ericsson, MD; Violeta I. Sanchez, BS | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 319 | Poster Presentation | The Tumor-intrinsic NLRP3 Inflammasome Establishes a Pulmonary Metastatic Niche via Type II Epithelial HSP70/TLR4 Signaling and Facilitates Disease Hyperprogression in Response to Immunotherapy | Balamayooran BT. Theivanthiran, PhD; Fang Liu, M.D.; Nicholas C. DeVito, MD; Michael P. Plebanek, PhD; Brent A. Hanks, MD, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Cytokine;Granulocyte;Immune suppression;Inflammation;MDSC;Myeloid cells;TLR;Tumor microenvironment;Tumor stroma | |
| 320 | Poster Presentation | Tumor cell-intrinsic signaling mediates T cell exclusion and promotes resistance to checkpoint blockade therapy in non-small cell lung cancer | Elen Torres-Mejia, PhD; Kim B. Nguyen, B.A.; Ellen Duong, Sc.B.; Stefani Spranger, PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Solid tumors;Stem cell/cancer-initiating cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 321 | Poster Presentation | PD-L1 checkpoint blockade eradicates residual leukemia in a mouse model of acute lymphoblastic leukemia by countering exhaustion of cytotoxic and effector CD4+ T-cells | Sean I. Tracy, MD,PhD; Sean I. Tracy, MD, PhD; Hrishi Venkatesh; Lynn Heltemes-Harris, PhD; Gregory Hubbard; Can Hekim, PhD; Michael A. Farrar | Checkpoint Blockade Therapy | B cell;Checkpoint blockade;Immune tolerance;Leukemia/Lymphoma;Regulatory T cell (Treg cell);T cell;Tumor evasion | |
| 322 | Poster Presentation | Melanoma-intrinsic hypoxia-inducible factor-1α results in diminished T cell accumulation within the tumor microenvironment | Emily Higgs; Thomas F. Gajewski, MD, PhD; Jonathan Trujillo, MD PhD | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor evasion;Tumor microenvironment | |
| 323 | Poster Presentation | Immunogenic Syngeneic Model MC38-OVA for the Preclinical Evaluation of Immune Evasion and Checkpoint Blockade | Jessie J. Wang, PhD; Kaixia Lian; Jia Zheng; Chenpan Nie; Annie An; Henry Q. Li | Checkpoint Blockade Therapy | Adoptive immunotherapy;Checkpoint blockade;Solid tumors;T cell | |
| 324 | Poster Presentation | Preclinical evaluation of anti-VISTA antibody CI-8993 in a syngeneic huVISTA-KI model | Fiona E. Scott, BSc (Hons) GDip IP Law; Christian W. Wichmann, PhD; Ingrid JG. Burvenich, PhD; Alexander F. McDonald, PhD; Nancy Guo, MSc; Angela Rigopoulos, MSc; Raul Soikes, MSc; Steven Angelides, MD; Reinhard von Roemeling, MD; Andrew M. Scott, MB BS, MD, FAHMS, FAICD, FAANMS | Checkpoint Blockade Therapy | Antibody;Checkpoint blockade;Targeted therapy | |
| 325 | Poster Presentation | Eliminating Tumor Immune Privilege through Immune Checkpoint Cytoreduction | Michelle Winkler, BS; Michael A. Curran, PhD | Checkpoint Blockade Therapy | Antibody;Bioinformatics;Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma | |
| 326 | Poster Presentation | The anti-TIGIT antibody M6223 induces significant anti-tumor efficacy and immune response via multiple mechanisms of action | Chunxiao Xu, PhD; Feng Jiang, PHD; Hui Huang, Ph.D.; Lindsay M. Webb; Sireesha Yalavarthi; Clotilde Bourin; Hong Wang; Natalya Belousova; Zhouxiang Chen; Christie Kelton; Dong Zhang, PhD; Joern-Peter Halle; Andree Blaukat; Jacques Moisan | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 327 | Poster Presentation | Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma | Jiajia Zhang, MD, MPH; Justina Caushi; Giacomo Oliveira, PhD; Boyang Zhang; Zhicheng Ji; Jarushka Naidoo, MD, MHS; Kristen A. Marrone, MD; Janis M. Taube, MD; Matthew D. Hellmann, MD; Julie R. Brahmer, MD, MS; Taha Merghoub, PhD; Patrick Forde; Srinivasan Yegnasubramanian; Catherine J. Wu, MD; Hongkai Ji; Andrew M. Pardoll, MD, PhD; Kellie Smith | Checkpoint Blockade Therapy | Checkpoint blockade;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs) | |
| 328 | Oral Presentation | Batf3 dendritic cells and 4-1BB/4-1BB ligand axis are required at the effector phase within the tumor microenvironment for anti-PD-L1 efficacy | Andrea Ziblat, PhD; Brendan L. Horton, PhD; Emily Higgs; Ken Hatogai, MD PhD; Thomas F. Gajewski, MD, PhD | Checkpoint Blockade Therapy | Antigen presenting cells;Checkpoint blockade;Costimulation;Dendritic cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
| 616 | Poster Presentation | CD47 blockade modulates immunosuppressive checkpoint molecules and cellular metabolism to sensitize triple-negative breast cancer tumors to immune checkpoint blockade therapy | Elizabeth R. Stirling, MS; Adam Wilson, .; Katherine L. Cook, PhD; Alexandra Thomas, MD; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Combination Immunotherapies | Biomarkers;Checkpoint blockade;Immune suppression;Metabolism;Solid tumors;Tumor microenvironment | |
| 619 | Poster Presentation | Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy | Svena Verma, BS; Rachana Maniyar, PhD; Myat K. Ko; Sadna Budhu, PhD; Inna Serganova; Roberta Zappasodi, PhD; Ronald Blasberg; Taha Merghoub, PhD; Jedd D. Wolchok, MD/PhD; Levi M. Mangarin, BS | Combination Immunotherapies | Metabolism | |
| 700 | Oral Presentation | Increasing MHC-I expression to potentiate immune checkpoint blockade therapy | Shengqing Gu, PhD; Wubing Zhang; Xiaoqing Wang; Peng Jiang; Nicole Traugh; Ziyi Li; Clifford Meyer; Blair Stewig; Yingtian Xie; Xia Bu; Michael P. Manos; Alba Font-Tello; Evisa Gjini, PhD; Ana Lako; Klothilda Lim; Jake Conway; Alok K. Tewari; Zexian Zeng; Avinash Das Sahu; Collin Tokheim; Jason L. Weirather, PhD; Jingxin Fu; Yi Zhang; Benjamin Kroger; Jin Hua Liang; Paloma Cejas; Gordon J. Freeman, PhD; Scott J. Rodig, MD, PhD; Henry W. Long; Benjamin E. Gewurz; F. Stephen Hodi, Jr., MD; Myles Brown; X Shirley Liu, PhD | Immune-stimulants and immune modulators | Checkpoint blockade;Gene expression | |
Late-Breaking | ||||||
| 947 | Poster Presentation | Recombinant Myxoma Virus MC509-N1 Demonstrates Antitumor Efficacy as Monotherapy and in Combination with Immune Checkpoint Inhibitors | Enkhtaivan Gansukh, PhD; Tommy Alain, PhD; Tae-Geuk Kim; Ye-Na Namgung; Ka-Yeon Son; Yeo-Jin Jeong; Yeon-Sook Lee; | Checkpoint Blockade Therapy | Checkpoint blockade;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment | |
Presented By:
